wellteq

BTV Highlights Promising Investment Opportunities

On Sat. Sept 25th at 5pm EST broadcast on FOX Business News - BTV-Business Television visits up-and-coming innovative investment opportunities.

Discover Companies to Invest In - Watch their TV feature!

Osisko Metals (TSXV: OM) (OTCQX:OMZNF) - As electric transportation rises in popularity, the zinc demand increases and Osisko is poised to take advantage with their advanced zinc projects.

Fobi AI (TSXV: FOBI) (OTCQB: FOBIF) - BTV showcases their innovative AI device that provides real time data connectivity to retailers for increased profitability.

Rritual Superfoods(CSE: RSF) - BTV visits a company aiming to be the premium brand in the superfood space with its mushrooms and herbal adaptogen products.

Desert Mountain Energy (TSXV: DME) (OTCQX: DMEHF) - From helping launch rockets to driving antibiotics deep into the lungs of COVID patients, helium has many uses and Desert Mountain is gearing up to meet this growing demand.

Giga Metals (TSXV: GIGA) (OTCQB: HNCKF) - With nickel as one of the key minerals required in EV batteries, Giga is on point with one of the world's largest undeveloped nickel-cobalt sulphide deposits.

Lexaria Bioscience (CSE: LXX) (NASDAQ: LEXX) - A leading bioscience company whose patented technology, DehydraTECH, provides a faster and more effective drug delivery method.

About BTV:

On air for more than 20 years, BTV - Business Television, a half-hour investment TV show, features analysts and emerging companies on location. With Hosts, Taylor Thoen and Jessica Katrichak, BTV provides viewers with investment opportunities.

TV BROADCAST NETWORKS and TIMES:
FOX Business News US: Sat. Sept 25th 5pm EST.

Suggest a Company to Feature!
Contact: (604) 664-7401 x3 info@b-tv.com
To receive news, click here to subscribe

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/97377

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Radiopharm Theranostics

Investor Webinar – 3pm AEST Tuesday 2 July

Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for areas of high unmet medical need, is pleased to announce that CEO and Managing Director Riccardo Canevari and Executive Chairman Paul Hopper will conduct an investor webinar to provide an update following announcement of the Company’s $70 million capital raising.

When: 3pm AEST, Tuesday 2 July 2024

Keep reading...Show less
Researcher in medical lab looking at sample with microscope.

Oncology Stocks: 8 Biggest NASDAQ Companies in 2024

The wide-ranging oncology market covers every area of cancer care, from diagnosis to treatment.

Coming in only after cardiovascular disease, cancer is the second leading cause of death worldwide; unsurprisingly, oncology is one of the biggest sectors in the life science space. With that in mind, biotechnology and pharmaceutical companies alike are working to develop best-in-class therapeutics for the treatment of various cancers, including lung, breast and prostate cancer.

At this point, their work is far from finished — Fortune Business Insights projects that the global oncology market will increase at a compound annual growth rate of 11.3 percent to reach US$518.25 billion in 2032.

As the global oncology market grows, investors who want exposure to companies working to treat cancer should consider taking a look at biotech and pharma companies with a focus on oncology drugs and testing.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Reinstatement to Quotation

Description

The suspension of trading in the securities of Radiopharm Theranostics Limited (‘RAD’) will be lifted immediately following the release by RAD of an announcement regarding its capital raising.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Receives Strategic Investment for up to A$18 million

Radiopharm Theranostics Limited (ASX:RAD) (Radiopharm or the Company), a developer of diagnostic and therapeutic radiopharmaceutical products, has entered into strategic agreements with Lantheus Holdings, Inc. (LNTH.NASDAQ), a leading radiopharmaceutical-focused company, and its affiliates (Lantheus). Lantheus has agreed to make an initial equity investment of A$7.5 million (US$4.99 million) and will have an option to invest a further A$7.5 million (US$5 million) within 6 months on the same terms. Additionally, Radiopharm has agreed to transfer two of its early preclinical assets to Lantheus for A$3.0 million (US$2.0 million) pursuant to a separate transfer and development agreement.

Keep reading...Show less
Radiopharm Theranostics

Radiopharm Theranostics Limited (ASX: RAD) – Trading Halt

Description

The securities of Radiopharm Theranostics Limited (‘RAD’) will be placed in trading halt at the request of RAD, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Monday, 24 June 2024 or when the announcement is released to the market.

Keep reading...Show less
Man holds hand to head as fragments break off representing Alzheimer's disease.

Alzheimer’s Disease Treatment Stocks: 3 Biggest NASDAQ Companies in 2024

Alzheimer’s disease treatment stocks are focused on Alzheimer’s disease, a degenerative brain disorder that results in declining memory and thinking skills and typically affects people in their mid-60s.

According to the Alzheimer’s Association, neurons in other areas of the brain also begin to deteriorate as Alzheimer’s disease gets worse, resulting in the loss of basic human functions and overall cognitive impairment.

This condition affects more than 6.9 million people in the US alone; it’s also the most common form of dementia and is the seventh leading cause of death in America. Treatments are available to alleviate Alzheimer’s disease symptoms, but because they do not affect the underlying causes of this neurodegenerative disease, they’re only a bandaid solution.

Keep reading...Show less

Latest Press Releases

Related News

×